Rentschler Biopharma launches gene therapy subsidiary
CDMO Rentschler Biopharma will establish a Center of Excellence for cell and gene therapy through a new UK subsidiary Rentschler ATMP Ltd.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 976 entries already.
CDMO Rentschler Biopharma will establish a Center of Excellence for cell and gene therapy through a new UK subsidiary Rentschler ATMP Ltd.
MicroRNA-based therapeutics developer InteRNA Technologies has closed an extended Series B round totaling 18.5m led by AurorA Science, an Italian biotech investment company.
The German Health Ministry has requested 6.2bn from the Federal Ministry of Finance to purchase up to 635 million additional doses of COVID-19 vaccines.
V-Bio Ventures has announced the first closing of its V-Bio Fund 2 at 78m. The fund is focussed on investments into early stage life sciences companies in Belgium and the […]
The transatlantic Abingworth Bioventures 8 Fund has been closed at $464m to invest in US, UK and European life science companies.
As rapidly spreading mutants of SARS-CoV-2 are emerging, two Tuebingen-based vaccine developers will develop multivalent COVID-19 vaccines.
German CDMO Rentschler Biopharma is expanding cCMP production of CureVac NVs RNA-based COVID-19 vaccine candidate CVnCoV.
Enthera Pharmaceuticals extends its 28m Series A financing from last July to a total of 35m as Roche Venture Fund joins the companys investor syndicate.
A US subsidiary of Hamburg-based Evotec SE has won a contract from the US government to produce antibodies against SARS-CoV-2.
Israels Omnix Medical has been granted 10.8m needed to start Phase I/II development of a potential AMR breaking drug in Gram-negative bugs.